Skip to search formSkip to main contentSkip to account menu

RFCNU

Known as: N-(2-chloroethyl)-1-ribofuranosyl-2',3'-isopropylidene-5'-(p-nitrobenzoate)-3-nitrosourea 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1986
1986
Three new nitrosourea analogs (CNCC, RFCNU, and chlorozotocin) had comparable activities in vivo against L1210 leukemia cells. In… 
1985
1985
L1210 leukemia was used to compare the antitumor activities of three nitrosoureas (chlorozotocin, RFCNU and CNCC) encapsulated in… 
1982
1982
The results of three phase II clinical trials with three new analogues belonging to the family of nitrosoureas are reported. One… 
1981
1981
Examined by flow cytofluorometric analysis, the DNA distribution of EMT 6 tumor cells was highly perturbed after one hour of in… 
1980
1980
The disposition of 1-(2-Chloroethyl)-3-[1′-(5′- p -nitrobenzoyl-2′,3′-isopropylidene)-α,β-d-ribofuranosyl]-1-nitrosourea (RFCNU… 
1980
1980
The disposition of 1-(2-chloroethyl)-3-[1'(5'-p-nitrobenzoyl-2',3'-isopropylidene)-alpha,beta-D-ribofuranosyl]-1-nitrosourea… 
1979
1979
Using high-performance liquid chromatography, the stability of RFCNU was monitored as a function of pH in aqueous buffers at 37… 
1975
1975
Four new nitrosourea derivatives represent an appreciable progress in the treatment and cure of L1210 leukemia. Their therapeutic…